(Q34560688)

3 August 2017

1 reference

title

Advances in the management of Anderson-Fabry disease: enzyme replacement therapy (English)

1 reference

enzyme replacement therapy

3 August 2017

main subject

0 references

1 reference

Gregory M Pastores

1

1 reference

3 August 2017

Ravi Thadhani

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Expert Opinion on Biological Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

325-333

1 reference

Fabry's disease: a multidisciplinary disorder

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Gaucher's disease: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

alpha-Galactosidase A deficient mice: a model of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Selective arterial distribution of cerebral hyperperfusion in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Plasma exchange removes glycosphingolipid in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.3.325

21 January 2018

Identifiers

DOI

10.1517/14712598.2.3.325

1 reference

3 August 2017

1 reference